Jubilant Life Sciences arm launches Remdesivir injection in the Indian market

Jubilant Life Sciences on Monday announced that its arm, Jubilant Generics, has launched remdesivir injection under the brand name ‘JUBI-R’ in the Indian market at a price of ₹4,700 per vial of 100 mg.

Jubilant Generics will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network, the company said in a release.

Jubilant had entered into a non-exclusive licensing agreement with US Gilead Sciences, Inc. In May, which that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India.


Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of Covid-19.

"It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries,” Shyam S. Bhartia, Chairman & Managing Director and Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited said in the company statement.

“The Company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs.”